Gradalis, Inc.
https://www.gradalisinc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gradalis, Inc.
PharmaMar Endures Second Recent Setback With Phase III Ovarian Cancer Failure
Zepsyre did not show a PFS advantage measured against a comparator regimen in platinum-resistant ovarian cancer, but the novel chemotherapy is being tested in nine other cancers.
Immuno-Oncology Outlook: Bavencio Leads PD-1/L1 Pack In Ovarian Cancer
Merck KGaA/Pfizer's Bavencio is likely to be the first checkpoint inhibitor to gain approval in ovarian cancer but Roche's Tecentriq is hot on its heels. The ovarian cancer pipeline boasts seven other late-stage drugs, including antibody-drug conjugates and small molecules, that are ready to ramp up competition on the market.
Start-Up Execs On The Move, June 2016
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Execs On The Move, June 2016
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice